Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

3(75.0%)

Phase 4

1(25.0%)

4Total

N/A(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06505616Not ApplicableCompleted

SOLFA Study to Explore the Thrombogenicity of a Dialyzer

Role: lead

NCT03714386Not ApplicableUnknown

Study to Explore Morbimortality in Patients Dialyzed With the Theranova HDx in Comparison to On-Line-Hemodiafiltration

Role: lead

NCT01939977Phase 4Completed

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.

Role: lead

NCT03319680Not ApplicableUnknown

Benefits of Hemodialysis With Citrate (ABC-treat) Study

Role: lead

NCT01903148Completed

Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations

Role: lead

All 5 trials loaded